论文部分内容阅读
目的:探讨miR-10a在FAB不同亚型急性髓系白血病(AML)中的表达及其与AML耐药性的关系。方法:应用实时定量聚合酶链反应(RT-PCR)方法检测miR-10a在急性髓系白血病细胞株HL-60、U937、HL-60/ADR(阿霉素耐药株)、40例初治AML患者及16例非恶性血液病患者骨髓细胞中的表达,并分析其与AML临床特征的相关关系。结果:miR-10a在HL-60细胞株中的表达高于U937细胞株中的表达(P<0.05),在初治AML患者中的表达高于非恶性血液病组中的表达(P<0.01),在AML M3型患者中的表达高于M1、M2、M4型中的表达(P<0.05),在HL-60/ADR耐药株中的表达明显高于敏感株HL-60中的表达(P<0.01);除M3型外,经一疗程标准方案诱导化疗后未完全缓解组的miR-10a表达高于完全缓解组中的表达(P<0.01)。结论:miR-10a的高表达可能与早幼粒细胞的过度增生有关,并且与非M3型的急性髓系白血病细胞的耐药密切相关。
Objective: To investigate the expression of miR-10a in different subtypes of Acute Myeloid Leukemia (AML) and its relationship with AML. Methods: Real-time quantitative polymerase chain reaction (RT-PCR) was used to detect miR-10a in HL-60, U937 and HL-60 / ADR cell lines AML patients and 16 cases of non-hematological malignancies bone marrow cells, and analyze the relationship between the clinical features of AML. Results: The expression of miR-10a in HL-60 cell line was higher than that in U937 cell line (P <0.05), and was higher in non-hematologic malignancies than in untreated AML patients (P <0.01) ) Was higher in AML M3 than in M1, M2 and M4 (P <0.05), and higher in HL-60 / ADR resistant than HL-60 (P <0.01). In addition to M3, the expression of miR-10a in incomplete remission group was higher than that in complete remission group (P <0.01) after a course standard chemotherapy. Conclusion: The overexpression of miR-10a may be related to the hyperproliferation of promyelocytic cells and is closely related to the resistance of non-M3 type acute myeloid leukemia cells.